1-14 of 14
Tara Masterson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Clinical Trials & Observations
Ola Landgren, Thomas J. Prior, Tara Masterson, Christoph Heuck, Orlando F. Bueno, Ajeeta B. Dash, Hermann Einsele, Hartmut Goldschmidt, Stefan Knop, Cong Li, Ulf-Henrik Mellqvist, Ian McFadden, Corina Oprea, Jeremy A. Ross, Mihaela Talpes, Jay R. Hydren, Jennifer M. Ahlstrom, Dickran Kazandjian, Niels Weinhold, Rick Zhang, Maryalice Stetler-Stevenson, Gerald Marti, Sean M. Devlin
Journal: Blood
Blood (2024) 144 (4): 359–367.
https://doi.org/10.1182/blood.2024024371
Published: 2024
Includes: Supplemental data
Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Cyrille Touzeau, Ajai Chari, Carolina Schinke, Monique C. Minnema, Jesus Berdeja, Albert Oriol, Niels WCJ Van De Donk, Paula Rodriguez Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Leo Rasche, Amrita Y. Krishnan, Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Katharine S. Gries, Kelly Kato, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Chris Heuck, Philippe Moreau, Jesús San-Miguel
Journal: Blood
Blood (2022) 140 (Supplement 1): 4447–4449.
https://doi.org/10.1182/blood-2022-162555
Published: 2022
Journal Articles

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique C. Minnema, Jesus Berdeja, Albert Oriol, Niels WCJ Van De Donk, Paula Rodriguez Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Jo Caers, Leo Rasche, Amrita Y. Krishnan, Deeksha Vishwamitra, Xuewen Ma, Xiang Qin, Katharine S. Gries, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D. Goldberg, Christoph Heuck, Jesús San-Miguel, Philippe Moreau
Journal: Blood
Blood (2022) 140 (Supplement 1): 384–387.
https://doi.org/10.1182/blood-2022-159707
Published: 2022
Journal Articles

Interim Results of a Time and Motion Survey Regarding Subcutaneous Versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma

Mary Slavcev, Allison Spinelli, MSc, Elisabeth Absalon, Tara Masterson, MSc, Chris Heuck, MD, Annette Lam, MSc, Erwin De Cock, MSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 30–31.
https://doi.org/10.1182/blood-2020-139995
Published: 2020
Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Ajai Chari, MD, Jesús San-Miguel, Helen McCarthy, MBBS, PhD, Kenshi Suzuki, MD PhD, Vania T.M. Hungria, MD PhD, Anna Sureda, MD PhD, Aurore Perrot, MD PhD, Cyrille Hulin, MD, Hila Magen, MD, Shinsuke Iida, MD PhD, Vladimir Maisnar, MD PhD MBA, Lionel Karlin, MD, Ludek Pour, MD, Dolly A. Parasrampuria, PhD, Tara Masterson, Michele Kosh, RN, BSN, Shiyi Yang, Maria L. Delioukina, MD, Ming Qi, MD PhD, Robin Carson, MD BA, Cyrille Touzeau, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3152.
https://doi.org/10.1182/blood-2019-123560
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update

Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Hareth Nahi, MD PhD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Christoph Heuck, Xiang Qin, Dolly A. Parasrampuria, PhD, Ming Qi, Nizar Bahlis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1865.
https://doi.org/10.1182/blood-2019-122765
Published: 2019
Journal Articles

Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba

Maria-Victoria Mateos, MD PhD, Saad Z. Usmani, MD, Sebastian Grosicki, MD PhD, Vladimir I. Vorobyev, MD PhD, Ivan Spicka, MD PhD Prof, Vania T.M. Hungria, MD PhD, Sibirina Korenkova, Nizar Bahlis, MD, Max Flogegard, Joan Bladé, MD PhD, Philippe Moreau, MD, Martin F. Kaiser, Shinsuke Iida, MD PhD, Jacob P. Laubach, MD, Tara Masterson, Kristen Anne Lantz, PhD, Lisa O'Rourke, MSN, RN, Xiang Qin, Dolly A. Parasrampuria, PhD, Christoph Heuck, Ming Qi, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1906.
https://doi.org/10.1182/blood-2019-122501
Published: 2019
Journal Articles

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

Clinical Trials & Observations
Saad Z. Usmani, Hareth Nahi, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Ajai Chari, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Peter Hellemans, Tara Masterson, Pamela L. Clemens, Man Luo, Kevin Liu, Jesus San-Miguel
Journal: Blood
Blood (2019) 134 (8): 668–677.
https://doi.org/10.1182/blood.2019000667
Published: 2019
Includes: Supplemental data
Journal Articles

Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Pamela L Clemens, PhD, Steven Xu, PhD, Melody Luo, PhD, Ajai Chari, MD, Saad Z. Usmani, MD, Maria-Victoria Mateos, MD PhD, Niels WCJ van de Donk, MD PhD, Jonathan L Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, MD DSc, Lotfi Benboubker, MD, Jesus F San-Miguel, MD PhD, X. Yu-Nien Sun, Andrew Farnsworth, Tara Masterson, Peter Hellemans, Ming Qi, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2006.
https://doi.org/10.1182/blood-2018-99-113161
Published: 2018
Journal Articles

Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Pavo, an Open-Label, Multicenter, Dose Escalation Phase 1b Study

Ajai Chari, Hareth Nahi, Maria-Victoria Mateos, MD, Henk M. Lokhorst, Jonathan L. Kaufman, MD, Philippe Moreau, MDPhD, Albert Oriol, MD, Torben Plesner, MD, Lotfi Benboubker, MD, Peter Hellemans, Tara Masterson, Pamela L Clemens, Kevin Liu, Jesus F. San-Miguel, MD, Saad Z Usmani, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 838.
https://doi.org/10.1182/blood.V130.Suppl_1.838.838
Published: 2017
Journal Articles

Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)

Saad Z Usmani, MD FACP, Hareth Nahi, Maria-Victoria Mateos, MD PhD, Henk M. Lokhorst, MD PhD, Ajai Chari, MD, Jonathan L. Kaufman, MD, Philippe Moreau, Albert Oriol, MD, Torben Plesner, Professor, Lotfi Benboubker, MD PhD, Peter Hellemans, MD, Tara Masterson, Pamela L Clemens, PhD, Tahamtan Ahmadi, MD, Kevin Liu, Jesús San-Miguel, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1149.
https://doi.org/10.1182/blood.V128.22.1149.1149
Published: 2016
Journal Articles

A Drug-Drug Interaction Study of Ibrutinib with Moderate and Strong CYP3A Inhibitors in Patients with B-Cell Malignancy

Jan de Jong, PhD, Peter Hellemans, MD, Severijn De Wilde, Daniel Patricia, Tara Masterson, Georgii Manikhas, MD PhD, Alexander Myasnikov, MD PhD, Dzhelil Osmanov, MD, Raul Cordoba, MD PhD, Carlos Panizo, Loeckie de Zwart, PhD, Jan Snoeys, PhD, Vijay Chauhan, PhD, James Jiao, PhD, Juthamas Sukbuntherng, PhD, Daniele Ouellet, PhD
Journal: Blood
Blood (2016) 128 (22): 3964.
https://doi.org/10.1182/blood.V128.22.3964.3964
Published: 2016
Journal Articles

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

Ajai Chari, MD, Sagar Lonial, MD, Attaya Suvannasankha, Joseph W. Fay, Bertrand Arnulf, Jainulabdeen J. Ifthikharuddin, Xiang Qin, Tara Masterson, Kerri Nottage, Jordan M Schecter, Tahamtan Ahmadi, Brendan Weiss, Amrita Krishnan, Suzanne Lentzsch
Journal: Blood
Blood (2015) 126 (23): 508.
https://doi.org/10.1182/blood.V126.23.508.508
Published: 2015
Journal Articles

An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma

Philippe Moreau, MD, Maria-Victoria Mateos, Joan Bladé, MD PhD, Lotfi Benboubker, MD PhD, Javier de la Rubia, MD PhD, Thierry Facon, MD, Raymond L. Comenzo, MD, Joseph W. Fay, MD, Xiang Qin, MS, Tara Masterson, MS, Jordan Schecter, MD, Tahamtan Ahmadi, MD, Jesus San Miguel, MD PhD
Journal: Blood
Blood (2014) 124 (21): 176.
https://doi.org/10.1182/blood.V124.21.176.176
Published: 2014